3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 4
2
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
6
Lymphoma
3
Lymphoma, T-Cell, Cutaneous
2
Hematologic Diseases
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
Doxorubicin
3
10-propargyl-10-deazaaminopterin
3
Vincristine
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Gemcitabine
2
Drug Therapy
2
Cyclophosphamide
2
Alemtuzumab
2
romidepsin
1
cc-486
1
belinostat
1
Vitamin B 12
1
Stem Cell Transplantation
1
Standard of Care
1
Specimen Handling
1
Prednisone
1
Practice Guidelines as Topic
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Leukapheresis
1
Hematopoietic Stem Cell Mobilization
1
Folic Acid
1
Etoposide
1
Cytarabine
1
Cladribine
1
Carmustine
1
Busulfan
1
Brentuximab Vedotin
1
Biopsy
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, T-Cell
×
Brentuximab Vedotin
×
Clear all
NCT01777152
2021-11-30
ECHELON-2
Seagen Inc.
Phase 3
Completed
452 enrolled
16 charts
1 FDA